Clinical case of rifampicin-resistant tuberculous meningitis in a child: features of diagnosis, management and outcomes

Authors

DOI:

https://doi.org/10.14739/2310-1210.2026.1.327746

Keywords:

tuberculosis, meningitis, children, drug resistance, diagnosis, outcomes

Abstract

Aim: to demonstrate, based on an original clinical observation, the features of diagnosis, clinical management, and outcomes of rifampicin-resistant tuberculous meningitis in a child.

Materials and methods. A clinical case of rifampicin-resistant tuberculous meningitis in a child treated in the Pediatric Unit at the clinical base of the Department of Phthisiology and Pulmonology of Zaporizhzhia State Medical and Pharmaceutical University, located at the Public Non-Profit Enterprise “Zaporizhzhia Regional Clinical and Diagnostic Center of Phthisiology and Pulmonology” of the Zaporizhzhia Regional Council.

Results. A child was admitted to the Pediatric Unit from the pediatric intensive care unit (ICU) with a diagnosis of acute tuberculous meningitis. The diagnosis was confirmed by cerebrospinal fluid analysis using the Xpert MTB/RIF Ultra assay, which detected Mycobacterium tuberculosis resistant to the first-line antituberculous medication rifampicin. At the time of transfer, chest radiography revealed no pulmonary abnormalities. Brain magnetic resonance imaging showed no focal pathology. During further evaluation, the child’s mother was diagnosed with chemoresistant tuberculosis. The child received antituberculous and symptomatic therapy prescribed by a neurologist in the ICU for more than four months. During follow-up, chest computed tomography revealed disseminated pulmonary involvement. Following completion of treatment, the child was cured; however, epileptic syndrome developed, requiring lifelong therapy.

Conclusions. Delayed diagnosis of tuberculous meningitis in children is a major risk factor for disability. The clinical presentation is nonspecific, with manifestations typically occurring at later stages of the disease. Management requires combined antituberculous, hormonal, and symptomatic therapy and close cooperation among physicians of various specialties. Rapid and timely diagnosis, screening of at-risk groups, and effective treatment significantly improve prognosis and reduce mortality and disability.

Author Biographies

Yu. V. Myronchuk, Zaporizhzhia State Medical and Pharmaceutical University

MD, PhD, Assistant of the Department of Phthisiology and Pulmonology

O. O. Pushnova, Zaporizhzhia Regional Clinical and Diagnostic Center of Phthysiatry and Pulmonology

MD, pediatric phthisiatrician

L. V. Taran, Zaporizhzhia Regional Clinical and Diagnostic Center of Phthysiatry and Pulmonology

MD, pediatric phthisiatrician

L. I. Chernyshova, Zaporizhzhia Regional Clinical and Diagnostic Center of Phthysiatry and Pulmonology

MD, Head of the Pediatric Department

O. V. Dvizov, Zaporizhzhia Regional Clinical and Diagnostic Center of Phthysiatry and Pulmonology

MD, radiologist

References

WHO. Global tuberculosis report 2023. Geneva: World Health Organization. 2023. Available from: https://iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf?sequence=1

Chen J, Wu J, Luo Y, Huang N. NELL2 as a potential marker of outcome in the cerebrospinal fluid of patients with tuberculous meningitis: preliminary results from a single-center observational study. Eur J Med Res. 2022;27(1):281. doi: https://doi.org/10.1186/s40001-022-00921-7

Saal CL, Springer P, Seddon JA, van Toorn R, Esterhuizen TM, Solomons RS. Risk factors of poor developmental outcome in children with tuberculous meningitis. Childs Nerv Syst. 2023;39(4):1029-39. doi: https://doi.org/10.1007/s00381-022-05791-2

Rahimi BA, Niazi N, Rahimi AF, Faizee MI, Khan MS, Taylor WR. Treatment outcomes and risk factors of death in childhood tuberculous meningitis in Kandahar, Afghanistan: a prospective observational cohort study. Trans R Soc Trop Med Hyg. 2022;116(12):1181-90. doi: https://doi.org/10.1093/trstmh/trac066

Madan M, Sehgal R, Tuli IP, Mehta A, Gera R. Outcome of tuberculous meningitis in children aged 9 months to 12 years at the end of intensive phase of treatment. Indian J Tuberc. 2023;70 Suppl 1:S104-15. doi: https://doi.org/10.1016/j.ijtb.2023.05.007

Donovan J, Cresswell FV, Thuong NT, Boulware DR, Thwaites GE, Bahr NC; Tuberculous Meningitis International Research Consortium. Xpert MTB/RIF Ultra for the Diagnosis of Tuberculous Meningitis: A Small Step Forward. Clin Infect Dis. 2020;71(8):2002-5. doi: https://doi.org/10.1093/cid/ciaa473

Daniel BD, Grace GA, Natrajan M. Tuberculous meningitis in children: Clinical management & outcome. Indian J Med Res. 2019;150(2):117-30. doi: https://doi.org/10.4103/ijmr.IJMR_786_17

du Preez K, Jenkins HE, Donald PR, Solomons RS, Graham SM, Schaaf HS, et al. Tuberculous Meningitis in Children: A Forgotten Public Health Emergency. Front Neurol. 2022;13:751133. doi: https://doi.org/10.3389/fneur.2022.751133

Nataprawira HM, Gafar F, Risan NA, Wulandari DA, Sudarwati S, Marais BJ, et al. Treatment Outcomes of Childhood Tuberculous Meningitis in a Real-World Retrospective Cohort, Bandung, Indonesia. Emerg Infect Dis. 2022;28(3):660-71. doi: https://doi.org/10.3201/eid2803.212230

Anjum N, Noureen N, Iqbal I. Clinical presentations and outcomes of the children with tuberculous meningitis: An experience at a tertiary care hospital. J Pak Med Assoc. 2018;68(1):10-5.

Tong J, Gao M, Chen Y, Wang J. A case report about a child with drug-resistant tuberculous meningitis. BMC Infect Dis. 2023;23(1):83. doi: https://doi.org/10.1186/s12879-023-07990-x

Pradhan NN, Paradkar MS, Kagal A, Valvi C, Kinikar A, Khwaja S, et al. Performance of Xpert® MTB/RIF and Xpert® Ultra for the diagnosis of tuberculous meningitis in children. Int J Tuberc Lung Dis. 2022;26(4):317-25. doi: https://doi.org/10.5588/ijtld.21.0388

Sharawat IK, Ramachandran A, Panda PK, Kumar V, Sherwani P, Bhat NK. Development and Validation of a Prognostic Model and Bedside Score for the Neurological Outcome in Children with Tuberculous Meningitis. Am J Trop Med Hyg. 2022;107(6):1288-94. doi: https://doi.org/10.4269/ajtmh.22-0253

Wasserman S, Donovan J, Kestelyn E, Watson JA, Aarnoutse RE, Barnacle JR, et al. Advancing the chemotherapy of tuberculous meningitis: a consensus view. Lancet Infect Dis. 2025;25(1):e47-e58. doi: https://doi.org/10.1016/S1473-3099(24)00512-7. Erratum in: Lancet Infect Dis. 2025;25(1):e13. doi: https://doi.org/10.1016/S1473-3099(24)00829-6

Downloads

Additional Files

Published

2026-02-11

How to Cite

1.
Myronchuk YV, Pushnova OO, Taran LV, Chernyshova LI, Dvizov OV. Clinical case of rifampicin-resistant tuberculous meningitis in a child: features of diagnosis, management and outcomes. Zaporozhye Medical Journal [Internet]. 2026Feb.11 [cited 2026Feb.13];28(1):89-98. Available from: https://zmj.zsmu.edu.ua/article/view/327746